Senores Pharmaceuticals Limited is set to launch its IPO. The IPO will open on 20 December 2024 (Friday) and close on 24 December 2024 (Tuesday). This is a Book Built issue. Through this issue, the company aims to raise approximately ₹582.11 crores from potential investors.
The IPO consists of a fresh issue of equity shares worth ₹5,00 Cr. and an offer for sale of up to 2,100,000 equity shares worth 82.11 Cr. The face value of the shares is ₹10 per share, with the price band yet to be disclosed. Investors can bid for a minimum lot size, which will be announced soon.
IPO Key Highlights
| Category | Detail | Information |
|---|---|---|
| Key Dates | IPO Open Date | 20 December, 2024 |
| IPO Close Date | 24 December, 2024 | |
| Pricing Information | Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share | |
| Offer Structure | Total Issue Size | 1,48,87,723 shares (amounting up to ₹582.11 Cr) |
| Fresh Issue | 1,27,87,723 shares (amounting up to ₹500.00 Cr) | |
| Offer for Sale | 21,00,000 shares of ₹10 (amounting up to ₹82.11 Cr) | |
| Investor Details | Lot Size | 38 Shares |
| Listing Exchange | BSE and NSE | |
| IPO Type | Book Built Issue |
Important Dates of the IPO
| Event | Date |
|---|---|
| IPO Open Date | Friday, December 20, 2024 |
| IPO Close Date | Tuesday, December 24, 2024 |
| Basis of Allotment | Thursday, December 26, 2024 |
| Initiation of Refunds | Friday, December 27, 2024 |
| Credit of Shares to Demat | Friday, December 27, 2024 |
| Listing Date | Monday, December 30, 2024 |
What is GMP of Senores Pharmaceuticals Ltd IPO Today?
As of December 20, 2024, the Grey Market Premium (GMP) for the Senores Pharmaceuticals Ltd IPO is ₹150. This indicates that the shares are expected to list at approximately ₹541 per share.
Note: GMP is an unofficial indicator and is based on market speculation; it does not guarantee actual listing performance.
Company Financial Standing
| Period | 30 Sep 2024 (₹ Crore) | FY24 (₹ Crore) | FY23 (₹ Crore) | FY22 (₹ Crore) |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 |
| Total Expenses | 153.95 | 192.40 | 26.58 | 13.49 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Net Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
Company’s Key Metrics (FY 2024)
| Key Performance Indicator | Value |
|---|---|
| Return on Capital Employed (ROCE) | 11.73% |
| Return on Equity (ROE) | 23.60% |
| Debt to Equity Ratio | 1.07 |
| Return on Net Worth (RoNW) | 23.60% |
| Price to Book Value (P/BV) | * |
| After Tax Profit Margin (%) | 15.25% |
| EBITDA Margin (%) | 20.70% |
| Net Asset Value (NAV) | ₹66.96 |
| Earnings Per Share (EPS) | ₹13.67 |
Lot Size and Application Amount
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail Investor (Minimum Lot) | 1 | 38 | ₹14,858 |
| Retail Investor (Maximum Lot) | 13 | 494 | ₹1,93,154 |
| Small HNI Investor (Minimum Lot) | 14 | 532 | ₹2,08,012 |
| Small HNI Investor (Maximum Lot) | 67 | 2,546 | ₹9,95,486 |
| Big HNI Investor (Minimum Lot) | 68 | 2,584 | ₹10,10,344 |
Investor Category-Wise Reservation
| Investor Category | Reservation |
|---|---|
| Shares Reserved for QIB | 75% of the Net Issue |
| Shares Reserved for Retail Investors | 10% of the Net Issue |
| Shares Reserved for Non-Institutional Investors | 15% of the Net Issue |
Net Cash Flow Overview
| Net Cash Flow | For the Period Ended 30 Sep 2024 (₹ in crores) | FY 2024 (₹ in crores) | FY 2023 (₹ in crores) | FY 2022 (₹ in crores) |
|---|---|---|---|---|
| Net Cash Flow from Operating Activities | 6.39 | -19.87 | -1.08 | -10.45 |
| Net Cash Flow from Investing Activities | -54.47 | -54.66 | -48.29 | -24.44 |
| Net Cash Flow from Financing Activities | 48.95 | 86.98 | 46.25 | 36.46 |
| Net Increase/(Decrease) in Cash and Bank Balance | 0.87 | 12.45 | -3.12 | 1.58 |
Country Wise Revenue Breakdown
| Countries | Period Ended Sep 30, 2024 (₹ in crores) | FY 24 (₹ in crores) | FY 23 (₹ in crores) | FY 22 (₹ in crores) |
|---|---|---|---|---|
| United States | 108.25 | 142.93 | 26.35 | 0.89 |
| Yemen | 2.67 | 10.79 | 0.00 | 0.00 |
| Nigeria | 11.97 | 10.68 | 0.00 | 0.00 |
| Ghana | 9.36 | 7.43 | 0.00 | 0.00 |
| Philippines | 5.47 | 3.61 | 0.00 | 0.00 |
| Total | 137.72 | 175.44 | 26.35 | 0.89 |
Revenue Breakdown by Manufacturing Facilities
| Manufacturing Facility | Period Ended Sep 30, 2024 (₹ in million) | FY 24 (₹ in million) | FY 23 (₹ in million) | FY 22 (₹ in million) |
|---|---|---|---|---|
| Atlanta Facility (A) | 759.03 | 986.80 | * | * |
| Chhatral Facility (B) | 601.77 | 442.02 | * | * |
| Naroda Facility (C) | 61.71 | 138.95 | * | * |
Key Objectives of the Issue
The fund raised through this IPO will be utilized for the following purposes:
- For capital expenditure at the Atlanta Facility.
- Repayment of certain company borrowings.
- Funding working capital requirements of the company.
- Funding inorganic growth through acquisitions and strategic initiatives.
- General corporate purposes.
Popular Questions
- What are the opening and closing dates for the Senores Pharmaceuticals public issue?
The offering opens on 20 December, 2024, and closes on 24 December, 2024. - Who are the lead managers for this issue?
The lead managers are Equirus Capital Private Limited, Ambit Private Limited, and Nuvama Wealth Management Limited. - Who is the registrar for this offer?
The registrar is Link Intime India Private Limited. - What is the price band for this public offering?
The price band is yet to be disclosed. - What is the minimum lot size for retail investors in this equity issue?
The lot size details have not been disclosed. - What are the main objectives of this fundraising initiative?
The funds will be used for Capital expenditure requirements for the company and subsidiaries, Repayment/prepayment of certain borrowings, Working capital funding, General corporate purposes etc. - On which stock exchanges will the shares be traded?
The equity shares will be listed on BSE and NSE. - What is the total size of the offering?
The total offer size includes a fresh issue up to ₹5,000 million and offer for sale of 2,100,000 equity shares. - When will the allotment and refund process commence?
Allotment will begin on 25 December, 2024, with refunds processed shortly thereafter. - When will the shares be credited to investors’ Demat accounts?
Shares will be credited to investors’ Demat accounts on 26 December, 2024. - What is the expected listing date for the company’s shares?
The shares are expected to list on 27 December, 2024.
It is always beneficial to read Draft Red Herring Prospectus (DRHP) and Red Herring Prospectus (RHP) carefully to better understand its financials and growth opportunities before making a decision.
Looking for more IPO reviews? Check out our IPO Dashboard for recent posts on other Main-board IPO & SME IPOs for the latest market updates.
Note: This article is based on the information received from the company’s official documents, including the Draft Red Herring Prospectus (DRHP) and Red Herring Prospectus (RHP). For up-to-date information on the Grey Market Premium (GMP) for the Senores Pharmaceuticals Ltd IPO, you may please check our Current GMP, where we will post the latest figures as soon as they are available.
Disclaimer: This article is for educational purposes only. We do not offer any advice on buying or selling securities. Please consult your financial advisor before investing in an IPO or any other securities to make sure that it suits your financial plans and risk tolerance.
Don’t miss out on the latest IPOs – Click here to Find Upcoming IPOs.
“Invest Smarter, Faster – Click Here to Open Your Free Demat Account Today!”
“If this article was useful to you, feel free to share it with others who might find it helpful. Your feedback is important, so drop your questions or thoughts in the comments—we’d love to hear from you!”
Looking for the latest updates on upcoming IPOs? Explore detailed insights, expert reviews, and key information on these trending IPOs:
Leave a comment